Erythropoietic Protoporphyria (EPP)
2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Tanabe Pharma AmericaNJ - Jersey City
2 programs1
1
DersimelagonPhase 31 trial
MT-7117 low dosePhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Tanabe Pharma AmericaDersimelagon
Tanabe Pharma AmericaMT-7117 low dose
Clinical Trials (2)
Total enrollment: 267 patients across 2 trials
INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP
Start: Dec 2023Est. completion: Jun 2026165 patients
Phase 3Active Not Recruiting
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria
Start: Jul 2018Est. completion: Sep 2019102 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.